IMV Joins World Ovarian Cancer Coalition and Ovarian Cancer Canada in Supporting Ovarian Cancer Day 2019
08 May 2019 - 9:05PM
Business Wire
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage
immuno-oncology corporation, today joins with World Ovarian Cancer
Coalition and Ovarian Cancer Canada in recognizing World Ovarian
Cancer Day (WOCD). This initiative aims to raise awareness of, and
bring hope to, the global challenges faced by women living with a
diagnosis of ovarian cancer.
“Ovarian cancer remains one of the most underserved,
difficult-to-treat forms of the disease,” said Frederic Ors, Chief
Executive Officer at IMV Inc. “IMV is committed to developing an
immunotherapy approach with the potential to make meaningful
difference in the lives of the women with ovarian cancer. We are
honored to support the World Ovarian Cancer Coalition and Ovarian
Cancer Canada, to be a part of the solution as we advance multiple
clinical studies of our product candidates in ovarian cancer, and
to amplify the patients’ voices and continue to drive awareness of
this urgent medical need.”
Over 150 ovarian cancer patient organizations from around the
world work together, year-round, as partners of the World Ovarian
Cancer Coalition. Each year on May 8th for WOCD, they come together
to raise awareness of ovarian cancer and the need for global action
to tackle this disease for every woman, no matter where she
lives.
Elisabeth Baugh, Chair of the World Ovarian Cancer Coalition,
commented, “Our ‘Every Woman Study,’ which surveyed more than 1500
women, found that two-thirds of women who had been diagnosed with
ovarian cancer had either not heard of it or knew nothing about the
disease prior to their diagnosis. This is why it is crucial that we
come together each year on World Ovarian Cancer Day to raise
awareness and speak with one voice in our fight against this
disease. I am proud to be part of a global community that speaks
out so loudly and passionately. I’m also enormously grateful for
the continued support of our partners.”
To demonstrate support for WOCD, IMV employees will wear teal –
the signature color of ovarian cancer awareness – and participate
in a social media campaign to spread awareness about ovarian
cancer. Those interested can join IMV, and other organizations
around the world, today in support of WOCD. Connect at
https://ovariancancerday.org/get-involved/
About World Ovarian Cancer Coalition
The World Ovarian Cancer Coalition (WOCC) is a not-for-profit
organization, established in 2016, working across the globe to
reduce the impact ovarian cancer has on the lives of women and
their loved ones. The creation of the World Ovarian Cancer
Coalition is a logical and powerful next step that builds on the
significant impact of the annual flagship ovarian cancer awareness
campaign – World Ovarian Cancer Day. Our mission is to ensure the
best possible chance of survival, and the best quality of life for
every woman with ovarian cancer – wherever she lives.
About IMV
IMV Inc. is a clinical stage biopharmaceutical company dedicated
to making immunotherapy more effective, more broadly applicable,
and more widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the
programming of immune cells in vivo, which are aimed at
generating powerful new synthetic therapeutic capabilities. IMV’s
lead candidate, DPX-Survivac, is a T cell-activating immunotherapy
that combines the utility of the platform with a target: survivin.
IMV is currently assessing DPX-Survivac as a monotherapy in
advanced ovarian cancer, as well as a combination therapy in
multiple clinical studies with Merck. Connect
at www.imv-inc.com.
IMV Forward-Looking Statements
This press release contains forward-looking information under
applicable securities law. All information that addresses
activities or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. In the press release, such forward-looking
statements include, but are not limited to, statements regarding
the FDA potentially granting accelerated regulatory
approval of DPX-Survivac. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Corporation, including access to
capital, the successful design and completion of clinical trials
and the receipt and timely receipt of all regulatory
approvals. IMV Inc. assumes no responsibility to update
forward-looking statements in this press release except as required
by law. These forward-looking statements involve known and unknown
risks and uncertainties and those risks and uncertainties include,
but are not limited to, our ability to access capital, the
successful and timely completion of clinical trials, the receipt of
all regulatory approvals and other risks detailed from time to time
in our ongoing quarterly filings and annual information form
Investors are cautioned not to rely on these forward-looking
statements and are encouraged to read IMV’s continuous disclosure
documents, including its current annual information form, as well
as its audited annual consolidated financial statements which are
available on SEDAR at www.sedar.com and on EDGAR
at www.sec.gov/edgar.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190508005176/en/
MEDIAAndrea Cohen, Sam Brown Inc.O: (917) 209-7163
E: andreacohen@sambrown.com
INVESTOR RELATIONSMarc Jasmin, IMV Senior
Director, Investor Relations and CommunicationsO: (902) 492-1819
ext: 1042M: (514) 917-9481 E: mjasmin@imv-inc.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024